Erosive osteoarthritis during treatment with bevacizumab and paclitaxel in a patient with recurrent papillary serous carcinoma of the ovary

A. Jaishuen; J. P. Berrios-Rivera; N. Sirisabya; H. G. Zheng; Y. Li; J. J. Kavanagh

doi:10.1111/j.1525-1438.2007.01023.x

Erosive osteoarthritis during treatment with bevacizumab and paclitaxel in a patient with recurrent papillary serous carcinoma of the ovary

A. Jaishuen
, J. P. Berrios-Rivera
, N. Sirisabya
, H. G. Zheng
, Y. Li
, J. J. Kavanagh

Department of Obstetrics & Gynecology

The University of Texas MD Anderson Cancer Center

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

Abstract

Bevacizumab (BVC) is currently used in recurrent ovarian cancer and as part of the initial treatment for ovarian cancer. The most serious toxicities associated with BVC include gastrointestinal perforations, delayed wound healing, and hemorrhage. Arthritis had never been addressed in patients who received BVC treatment. This is the first case report of arthritis emergence linked to BVC administration. A 59-year-old female with recurrent ovarian cancer received multiple hormonal and cytotoxic regimens for 5 years and then developed erosive osteoarthritis of the hands secondary to BVC and paclitaxel. This effect was confirmed by a significant improvement in her symptoms and signs, after treatment was discontinued.

Original language	English
Pages (from-to)	379-383
Number of pages	5
Journal	International Journal of Gynecological Cancer
Volume	18
Issue number	2
DOIs	https://doi.org/10.1111/j.1525-1438.2007.01023.x
Publication status	Published - Mar 2008

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Arthritis
Bevacizumab
Ovarian cancer
Vascular endothelial growth factor

Access to Document

10.1111/j.1525-1438.2007.01023.x

Cite this

@article{1e222c4ee35e482b8e70a20aaab2146b,

title = "Erosive osteoarthritis during treatment with bevacizumab and paclitaxel in a patient with recurrent papillary serous carcinoma of the ovary",

abstract = "Bevacizumab (BVC) is currently used in recurrent ovarian cancer and as part of the initial treatment for ovarian cancer. The most serious toxicities associated with BVC include gastrointestinal perforations, delayed wound healing, and hemorrhage. Arthritis had never been addressed in patients who received BVC treatment. This is the first case report of arthritis emergence linked to BVC administration. A 59-year-old female with recurrent ovarian cancer received multiple hormonal and cytotoxic regimens for 5 years and then developed erosive osteoarthritis of the hands secondary to BVC and paclitaxel. This effect was confirmed by a significant improvement in her symptoms and signs, after treatment was discontinued.",

keywords = "Arthritis, Bevacizumab, Ovarian cancer, Vascular endothelial growth factor",

author = "A. Jaishuen and Berrios-Rivera, \{J. P.\} and N. Sirisabya and Zheng, \{H. G.\} and Y. Li and Kavanagh, \{J. J.\}",

year = "2008",

month = mar,

doi = "10.1111/j.1525-1438.2007.01023.x",

language = "English",

volume = "18",

pages = "379--383",

journal = "International Journal of Gynecological Cancer",

issn = "1048-891X",

publisher = "Elsevier Inc.",

number = "2",

}

TY - JOUR

T1 - Erosive osteoarthritis during treatment with bevacizumab and paclitaxel in a patient with recurrent papillary serous carcinoma of the ovary

AU - Jaishuen, A.

AU - Berrios-Rivera, J. P.

AU - Sirisabya, N.

AU - Zheng, H. G.

AU - Li, Y.

AU - Kavanagh, J. J.

PY - 2008/3

Y1 - 2008/3

N2 - Bevacizumab (BVC) is currently used in recurrent ovarian cancer and as part of the initial treatment for ovarian cancer. The most serious toxicities associated with BVC include gastrointestinal perforations, delayed wound healing, and hemorrhage. Arthritis had never been addressed in patients who received BVC treatment. This is the first case report of arthritis emergence linked to BVC administration. A 59-year-old female with recurrent ovarian cancer received multiple hormonal and cytotoxic regimens for 5 years and then developed erosive osteoarthritis of the hands secondary to BVC and paclitaxel. This effect was confirmed by a significant improvement in her symptoms and signs, after treatment was discontinued.

AB - Bevacizumab (BVC) is currently used in recurrent ovarian cancer and as part of the initial treatment for ovarian cancer. The most serious toxicities associated with BVC include gastrointestinal perforations, delayed wound healing, and hemorrhage. Arthritis had never been addressed in patients who received BVC treatment. This is the first case report of arthritis emergence linked to BVC administration. A 59-year-old female with recurrent ovarian cancer received multiple hormonal and cytotoxic regimens for 5 years and then developed erosive osteoarthritis of the hands secondary to BVC and paclitaxel. This effect was confirmed by a significant improvement in her symptoms and signs, after treatment was discontinued.

KW - Arthritis

KW - Bevacizumab

KW - Ovarian cancer

KW - Vascular endothelial growth factor

UR - https://www.scopus.com/pages/publications/40549104502

U2 - 10.1111/j.1525-1438.2007.01023.x

DO - 10.1111/j.1525-1438.2007.01023.x

M3 - Article

C2 - 17624988

AN - SCOPUS:40549104502

SN - 1048-891X

VL - 18

SP - 379

EP - 383

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

IS - 2

ER -

Erosive osteoarthritis during treatment with bevacizumab and paclitaxel in a patient with recurrent papillary serous carcinoma of the ovary

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this